Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
ProFound Cloud, powered by Google Cloud architecture and Google’s Health AI innovations, redefines accessibility to critical insights, empowering radiologists in early breast cancer detectionNew partnership with Densitas provides end-to-end breast health solution ensuring every aspect of a woman’s breast health journey is addressedEnhanced ProFound Detection Workstation features streamline mammogram interpretation for radiologists NASHUA, N.H., April 11, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASD
Provides a holistic breast health solution, including breast cancer screening focused on quality, safety and efficiency, breast cancer detection, breast density assessment, and risk evaluationExpands access to iCAD’s AI-powered ProFound Breast Health Suite and Densitas’ AI solutions to patients and medical professionals worldwide NASHUA, N.H. and HALIFAX, Nova Scotia, April 09, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global leader in clinically proven AI-powered cancer detection so
Study confirms iCAD’s Breast Arterial Calcification AI Algorithm successfully detects calcification of breast vessels, an indicator of cardiovascular disease, from mammogramsNASHUA, N.H., April 08, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global leader in clinically proven AI-powered cancer detection solutions, announced today that new data indicates its AI-powered solution effectively uncovers calcium deposits in the breast vessels, a sign of possible cardiovascular disease in wome
iCAD implements ProFound AI Detection to improve mammography reading and breast cancer detection in low-resource institutions and medically underserved communitiesNASHUA, N.H., April 03, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global leader in clinically proven AI-powered cancer detection solutions, is proud to announce a philanthropic global health collaboration with RAD-AID International. RAD-AID, a non-profit charitable organization dedicated to improving radiology healthcare in
ProFound Cloud redefines accessibility to critical insights, empowering radiologists in early breast cancer detectionNASHUA, N.H., April 02, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) a global leader in clinically proven AI-powered cancer detection solutions, today announced commercial availability of ProFound Cloud. The innovative Software-as-a-Service (SaaS) platform provides medical providers with a cost-effective, secure, and scalable means to access and deploy the latest ProFound Br
Newly released capabilities -- limiting the number of marks on a 3D view, color-coding lesion marks, and color-coding the ProFound Scorecard -- enhance radiologists' interpretability and efficiencyNASHUA, N.H., March 19, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global leader in clinically proven AI-powered solutions that enable medical providers to accurately and reliably detect cancer earlier and improve patient outcomes, announced new, advanced workstation features for ProFound De
The market is overlooking many stocks that could benefit from the proliferation of AI over the longer term. There are companies using AI to solve real-world problems, and others providing the raw materials that enable the AI boom to progress. We’re even seeing the undervaluing of companies whose chips enable AI to be produced and work its magic, or that build and run the data centers that host the processors that AI utilizes. With that said, here are three undervalued AI stocks for long-term inv
iCAD, Inc. (NASDAQ:ICAD) Q4 2023 Earnings Call Transcript March 12, 2024 iCAD, Inc. beats earnings expectations. Reported EPS is $0.05, expectations were $-0.05. iCAD, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Greetings and welcome to the iCAD Incorporated […]
Q4 2023 ICAD Inc Earnings Call
Annual Recurring Revenue of $8.7 million, an increase of 15% year-over-yearFull-Year Operating Cash Flow ($5) million vs. ($12.8) million prior yearYear ending cash balance of $21.7M NASHUA, N.H., March 12, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) a global leader in clinically proven AI-powered solutions that enable medical providers to accurately and reliably detect cancer earlier and improve patient outcomes, today announced results for its fiscal fourth quarter and full year ended D